Here is an article in English about Cassava Sciences’ license deal with Yale University:
Cassava Sciences Signs License Deal with Yale University, Stock Soars
Burlington, MA, USA – Biotechnology company Cassava Sciences, Inc. (NASDAQ: SAVA) has announced that it has signed a license agreement with Yale University to develop a novel gene therapy for a range of neurological diseases, including amyotrophic lateral sclerosis (ALS), multiple system atrophy (MSA), and frontotemporal dementia (FTD).
Under the terms of the agreement, Cassava Sciences will have exclusive rights to develop and commercialize gene therapies based on the intellectual property of Yale University, which is led by Dr. Robert H. Brown, a renowned expert in the field of neuroscience. The license deal gives Cassava Sciences access to a crucial component of AAV, a type of viral vector used in gene therapy.
The agreement is a significant milestone for Cassava Sciences, which has been developing gene therapies for various neurological disorders using its proprietary AAV-based technology. The company’s lead program, CS-003, is currently in Phase 2 clinical trials for the treatment of patients with ALS, a progressive neurodegenerative disorder that affects millions of people worldwide.
"We are thrilled to partner with Yale University, a leading institution in the field of neuroscience, to develop groundbreaking gene therapies for debilitating neurological diseases," said Cameron Durrant, President and Chief Executive Officer of Cassava Sciences. "The licensed technology from Yale University is a critical component of our AAV platform, and we believe it will enable us to accelerate the development of our pipeline of gene therapies."
Under the terms of the agreement, Yale University will receive significant royalties on the sales of any products that arise from the licensed technology, as well as potential milestone payments and equity investments. Cassava Sciences will also perform certain research and development activities in collaboration with Yale University researchers.
The stock of Cassava Sciences (SAVA) surged over 14% in pre-market trading following the announcement, as news of the license deal spread. The deal is seen as a significant step forward for the company, which has been working towards developing innovative gene therapies for various neurological disorders.
Overall, the partnership between Cassava Sciences and Yale University is expected to accelerate the development of novel gene therapies for patients suffering from neurological diseases, and represents a significant milestone for the company and the scientific community at large.
